Statins and their role in pre-percutaneous coronary intervention

被引：27

作者：

Melfi R. ^{[1
]}

Nusca A. ^{[1
]}

Patti G. ^{[1
]}

Di Sciascio G. ^{[1
]}

机构：

[1] Department of Cardiovascular Sciences, Campus Bio-Medico University, 00128 Rome

来源：

Current Cardiology Reports | 2010年 / 12卷 / 4期

关键词：

Acute coronary syndrome; Chronic angina; Myocardial infarction; Percutaneous coronary intervention; Statins;

D O I：

10.1007/s11886-010-0110-0

中图分类号：

学科分类号：

摘要：

Lipid-lowering therapy with statins reduces the risk of cardiovascular events in patients with coronary artery disease. Recent in vitro and in vivo studies demonstrated a low-density lipoprotein-independent action of this class of drugs, which appears to modulate endothelial function, inflammation, and thrombosis. Randomized studies showed a beneficial effect of short-term statin pretreatment in reducing periprocedural cardiac marker release in patients undergoing percutaneous coronary intervention (PCI). In particular, the ARMYDA (Atorvastatin for Reduction of Myocardial Damage During Angioplasty) investigators- initially in stable angina patients, then in patients with acute coronary syndrome, and then in patients already on chronic statin therapy-demonstrated an improvement in 30-day major adverse cardiac event rates, which were driven by a reduced rate of periprocedural myocardial infarction. Moreover, statin therapy at the time of PCI significantly decreased the incidence of contrast-induced nephropathy. These observations support high-dose statin pretreatment in all patients who are candidates for PCI. © Springer Science+Business Media, LLC 2010.

引用

页码：295 / 301

页数：6

共 47 条

[1]

Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4 S) [no authors listed], Lancet, 344, pp. 1383-1389, (1994)

[2]

MRC/BHF heart protection study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: A randomized placebo-controlled trial. Heart Protection Study Investigators [no authors listed], Lancet, 360, pp. 7-22, (2002)

[3]

Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) study group [no authors listed], N Engl J Med, 339, pp. 1349-1357, (1998)

[4]

Davignon J., Beneficial cardiovascular pleiotropic effects of statins, Circulation, 109, pp. 39-43, (2004)

[5]

Morikawa S., Takabe W., Mataki C., Et al., The effect of statins on mRNA levels of genes related to inflammation, coagulation, and vascular constriction in HUVEC. Human umbilical vein endothelial cells, J Atheroscler Thromb, 9, pp. 178-183, (2002)

[6]

Abdelmeguid A.E., Topol E.J., Whitlow P.L., Et al., Significance of mild transient release of creatine-kinase MB fraction after percutaneous coronary interventions, Circulation, 94, pp. 1528-1536, (1996)

[7]

Brener S.J., Ellis S.G., Schneider J., Topol E.J., Frequency and longterm impact of myonecrosis after coronary stenting, Eur Heart J, 23, pp. 869-876, (2002)

[8]

Thygesen K., Alpert J.S., White H.D., Et al., Universal definition of myocardial infarction, Circulation, 116, pp. 2634-2653, (2007)

[9]

Ioannidis J.P., Karvouni E., Katritis D.G., Mortality risk conferred by small elevations of creatinine kinase-MB isoenzyme after percutaneous intervention, J Am Coll Cardiol, 42, pp. 1406-1411, (2003)

[10]

Turer A.T., Mahaffey K.W., Gallup D., Et al., Enzyme estimates of infarct size correlate with functional and clinical outcomes in the setting of ST-segment elevation myocardial infarction, Curr Control Trials Cardiovasc Med, 6, pp. 12-15, (2005)

← 1 2 3 4 5 →